What is it about?

Review on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against Pseudomonas.

Featured Image

Why is it important?

Multidrug-resistant Pseudomonas aeruginosa infections are increasingly common and very difficult to treat. By gathering in one place what is known about intravenous fosfomycin - how it works, how it reaches infected tissues, its action against biofilm and its synergy with other antibiotics - this review helps clinicians decide when and how to use this old drug as part of combination therapy.

Perspectives

Fosfomycin is an old molecule with a surprising second life. In our daily practice we often face Pseudomonas infections with very few therapeutic options, and I wanted to offer colleagues a practical, critical overview of when this drug can really make a difference.

Professor Stefano Di Bella
Universita degli Studi di Trieste

Read the Original

This page is a summary of: Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections, Antibiotics, November 2023, MDPI AG,
DOI: 10.3390/antibiotics12121653.
You can read the full text:

Read

Contributors

The following have contributed to this page